2. SCLERITIS
Anterior Posterior (6%)
Diffuse
(75%)
Nodular
(14%)
Necrotizing
(5%)
With
inflammation (4%)
• Vaso-occlusive necrotizing scleritis
• Granulomatous necrotizing scleritis
• Surgically induced necrotising scleritis (SINS)
Without
inflammation (1%)
• Scleromalacia perforans
Sainz de la Maza, M., Molina, N., Gonzalez-Gonzalez, L. A., Doctor, P. P., Tauber, J., & Foster, C. S. (2012). Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology, 119(1),
43–50. https://doi.org/10.1016/j.ophtha.2011.07.013
3. SYMPTOMS
• Severe & boring eye pain – awake at night
• Worsen with eye movement, with touch.
• May radiate ipsilateral to face, cheek & jaw.
• Gradual/acute onset red eye.
• Tearing, photophobia, decrease in vision.
• Recurrent episode is common.
4. • Deep episcleral plexus
dilated
• Tender & immobile
nodule
• Bluish violaceous hue
(observed in natural light)
• Scleral vessels do not
blanch vs episcleritis
(on application of topical phenylephrine 2.5%)
• Local/ diffuse
violaceous nodular
• Thin, bluish
sclera
SIGNS
• Scleral edema, intense
hyperemia
• Necrotic/avascular
plaques surrounded
by mildly dilated
episcleral vessels.
!!! Before drop phenylephrine, test for
tenderness with cotton bud.
5. Slit-beam view nodular Episcleritis vs. Scleritis
A slit lamp section shows an underlying flat anterior
scleral surface, indicating the absence of scleritis.
Deep beam is not displaced above the scleral
surface
Slit illumination shows superficial
displacement of the entire
beam
7. INVESTIGATION
• B-scan: T-sign
(suggestive of posterior scleritis)
• Complete blood count (CBC)
• ESR/CRP
• Serological tests:
o Rheumatoid factor (R.A factor)
o ANA (antinuclear antibodies)
o Anti ds DNA antibody
o ANCA (antineutrophil cytoplasmic antibodies)
o VDRL, FTA-ABS
Hyporeflectivity from optic nerve and fluid
under Tenon’s capsule
• Fundus angiography
• OCT
• Urine sediment
• Chest X-ray
• Tuberculin skin tests
9. TREATMENT
• Systemic treatment:
• Adequate control of the underlying condition.
• Oral NSAID
• Oral Prednisolone
• Intravenous methylprednisolone
• Immunosuppressive therapy
• Surgical treatment:
• Scleral grafting
• Biologic immunomodulatory agents
• Alkylating agents
• Scleral debridement
• Systemic (& topical)
antimicrobials
Infectious
scleritis
!!! Can start steroid as well
to control inflammation
!!! Sclera to sclera grafting is
hard. Common use amniotic
membrane grafting.
10. PROGNOSIS
• Nonnecrotizing noninfectious anterior
(diffuse or nodular) scleritis :
• Necrotizing scleritis, posterior scleritis or
infectious scleritis :
Good prognosis with treatment
High risk of permanent vision loss
At risk of higher mortality rates
11. Diffuse anterior scleritis / diffuse non-necrotizing anterior scleritis Nodular anterior scleritis / nodular non-necrotizing anterior scleritis
Vaso-occlusive necrotizing anterior scleritis Granulomatous necrotizing scleritis SINS following trabeculectomy
Patient with rheumatoid arthritis. Asymptomatic necrotic patch Moderate Severe thinning and exposure of uvea
Necrotizing anterior scleritis without inflammation (Scleromalacia perforans)
Necrotizing anterior scleritis with inflammation
12. REFERENCES
• 2019-2020 BCSC (Basic and Clinical Science Course), Section 09:
Uveitis and Ocular Inflammation (MAJOR REVISION)
• 2016. The Wills Eye Manual. 7th ed. Philadelphia, PA: Lippincott
Williams and Wilkins.